Lactiga develops novel mucosal antibodies derived from human breastmilk and specializes in secretory IgA (sIgA)-based therapeutics using proprietary technologies. Its lead asset, LCTG-001, is described as the first-ever sIgA mucosally-targeted replacement therapy for patients with compromised immune function. LCTG-001 targets patients with conditions such as Common Variable Immune Deficiency (CVID) who lack mucosal immune protection. The program has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Lactiga plans to use recent funding to complete key nonclinical studies and prepare for first-in-human trials. The company emphasizes treating rare pediatric diseases and reducing mortality and chronic infections in vulnerable populations. Lactiga Therapeutics develops antibody programs derived from human milk for patients with primary immunodeficiencies and COVID-19, based on patented technologies. The company has reported positive topline nonclinical efficacy results and is advancing two primary preclinical programs, LCTG-001 (Common Variable Immunodeficiency) and LCTG-002 (COVID-19 and its variants). Lactiga is based in New Jersey and Toronto and plans to use its recent financing and grants to complete preclinical studies and strengthen its intellectual property portfolio. The company intends to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and start human clinical trials in 2023. Lactiga is collaborating with McMaster University and has secured nondilutive support from programs including the New Jersey Commission on Science, Innovation and Technology (CSIT) and Innovation Factory’s SOPHIE program. The funding and grants are positioned to advance R&D, commercialization preparation, and follow-on investment potential. Lactiga is a biotherapeutics company developing anti-infective biologics derived from maternal antibodies in discarded breast milk. Its lead candidate, LCTG-001, is designed for patients with Primary Immunodeficiency Diseases, including Selective IgA Deficiency and Common Variable Immunodeficiency. LCTG-001 is in preclinical studies and is also being evaluated as a potential treatment for COVID-19. The company has secured a $2.0 million NIH R01 Emergency Award to advance its COVID-19 therapeutics program in collaboration with the Icahn School of Medicine at Mount Sinai. Lactiga owns its intellectual property, received patent approval in Canada in 2020, and has patents pending in the US, EU, and Japan with planned filings in Asia including China. The company has won multiple awards and competition placements, and is working to expand relationships with breast milk banks across North America and Europe.

Total raised

$2M

Funding rounds

4

Latest round

Seed

Latest activity

Sep 2022